Africa, Asia and the Pacific > President's Emergency Plan for AIDS Relief

On September 8, 2011, the Food and Drug Administration (FDA) granted tentative approval for lamivudine and tenofovir DF fixed dose combination tablets, 300 mg/300 mg, co-packaged with nevirapine Tablets, 200 mg, indicated for use alone or in combination with other antiretrovirals for the treatment of HIV-1 infection, manufactured by Matrix Laboratories Limited of Hyderabad, India.
FDA's tentative approval means that although a product meets all of the safety, efficacy, and manufacturing quality standards required for marketing in the U.S., existing patents and/or proprietary issues currently prevent marketing of the product in the United States. Tentative approval, however, does qualify the product for consideration for purchase under the President's Emergency Plan for AIDS Relief, or PEPFAR program.
As with all generic applications, FDA conducts an on-site inspection of the manufacturing facilities and of the facilities performing the bioequivalence studies prior to granting approval or tentative approval to evaluate the ability of the manufacturer to produce a quality product and to assess the quality of the bioequivalence data supporting the application.
This product was reviewed for PEPFAR under the FDA guidance titled Fixed Dose Combinations, Co-Packaged Drug Products, and Single-Entity Versions of Previously approved Antiretrovirals for the Treatment of HIV, intended to encourage sponsors to submit applications for combination and co-packaged products, and to facilitate submission of such applications to FDA.
You can find a complete list of all Approved and Tentatively Approved Antiretrovirals in Association with the President's Emergency Plan on the FDA web site.
Richard Klein
Office of Special Health Issues
Food and Drug Administration
Kimberly Struble
Division of Antiviral Products
Food and Drug Administration

Africa, Asia and the Pacific > President's Emergency Plan for AIDS Relief: - Enviado mediante la barra Google